for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Concert Pharmaceuticals Inc

CNCE.OQ

Latest Trade

6.80USD

Change

-0.15(-2.16%)

Volume

29,180

Today's Range

6.70

 - 

6.93

52 Week Range

5.36

 - 

17.80

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Concert Pharmaceuticals Q3 Loss Per Share $0.72

Concert Pharmaceuticals Inc <CNCE.O>::CONCERT PHARMACEUTICALS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q3 LOSS PER SHARE $0.72.Q3 EARNINGS PER SHARE ESTIMATE $-0.83 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF SEPTEMBER 30, 2019 TOTALED $121.5 MILLION.CONCERT PHARMACEUTICALS- EXPECTS CASH, CASH EQUIVALENTS & INVESTMENTS TO BE SUFFICIENT TO FUND CO THROUGH 2020 UNDER CURRENT OPERATING PLAN.

Concert Pharma Reports Positive CTP-543 Results From Phase 2 Alopecia Areata Trial

Sept 3 (Reuters) - Concert Pharmaceuticals Inc <CNCE.O>::CONCERT PHARMACEUTICALS REPORTS POSITIVE CTP-543 RESULTS FROM PHASE 2 ALOPECIA AREATA TRIAL.CONCERT PHARMACEUTICALS REPORTS POSITIVE CTP-543 RESULTS FROM PHASE 2 ALOPECIA AREATA TRIAL.CONCERT PHARMACEUTICALS INC - CTP-543 ACHIEVED ITS PRIMARY ENDPOINT IN 8 MG AND 12 MG TWICE-DAILY DOSING COHORTS.CONCERT PHARMACEUTICALS INC - ADVANCEMENT INTO PHASE 3 EVALUATION PLANNED IN 2020.CONCERT PHARMACEUTICALS INC - CTP-543 ACHIEVED ITS PRIMARY ENDPOINT IN 8 MG AND 12 MG TWICE-DAILY DOSING COHORTS.

Concert Pharmaceuticals Q2 Loss Per Share $0.78

Aug 1 (Reuters) - Concert Pharmaceuticals Inc <CNCE.O>::CONCERT PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q2 LOSS PER SHARE $0.78.Q2 EARNINGS PER SHARE ESTIMATE $-0.89 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE 30, 2019, TOTALED $136.6 MILLION.CONCERT PHARMACEUTICALS - EXPECTS CASH, CASH EQUIVALENTS AND INVESTMENTS TO BE SUFFICIENT TO FUND COMPANY INTO SECOND HALF OF 2020.

Concert Pharma Reports Positive Results From Early-Stage Studies Testing Its Experimental Schizophrenia Treatment

June 12 (Reuters) - Concert Pharmaceuticals Inc <CNCE.O>::CONCERT PHARMACEUTICALS REPORTS POSITIVE RESULTS FROM PHASE 1 STUDIES EVALUATING CTP-692 IN HEALTHY VOLUNTEERS.CONCERT PHARMACEUTICALS INC - EXPECTS TO INITIATE A PHASE 2 TRIAL IN PATIENTS WITH SCHIZOPHRENIA IN Q4 OF 2019.CONCERT PHARMA - SAFETY ASSESSMENTS IN SINGLE- & MULTIPLE-ASCENDING DOSE TRIALS IN HEALTHY VOLUNTEERS SHOWED DRUG WAS WELL TOLERATED OVER DOSE RANGES TESTED.CONCERT PHARMACEUTICALS - STUDY SHOWED KEY BLOOD AND URINE MARKERS OF KIDNEY FUNCTION DID NOT INDICATE ANY SIGNS OF RENAL IMPAIRMENT.

Concert Pharmaceuticals Q1 Loss Per Share $0.93

Concert Pharmaceuticals Inc <CNCE.O>::CONCERT PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.93.Q1 REVENUE $1.0 MILLION VERSUS $10.5 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.62 -- REFINITIV IBES DATA.Q1 REVENUE ESTIMATE $5.3 MILLION -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF MARCH 31, 2019, TOTALED $153.8 MILLION.

Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial Of CTP-692 As An Adjunctive Treatment For Schizophrenia

April 10 (Reuters) - Concert Pharmaceuticals Inc <CNCE.O>::CONCERT PHARMACEUTICALS INITIATES PHASE 1 MULTIPLE-ASCENDING DOSE TRIAL OF CTP-692 AS AN ADJUNCTIVE TREATMENT FOR SCHIZOPHRENIA.CONCERT PHARMACEUTICALS INC - TOPLINE DATA FROM BOTH SINGLE-AND MULTIPLE-ASCENDING CTP-692 PHASE 1 TRIALS ARE EXPECTED IN Q2 OF 2019.CONCERT PHARMACEUTICALS INC - CTP-692 WAS FOUND TO BE WELL TOLERATED IN HEALTHY VOLUNTEERS.CONCERT PHARMACEUTICALS INC - NO SERIOUS ADVERSE EVENTS WERE REPORTED.

Concert Pharmaceuticals Says Intend To Appeal Decision From Patent Trial

April 8 (Reuters) - Concert Pharmaceuticals Inc <CNCE.O>::CONCERT PHARMACEUTICALS ANNOUNCES DECISION FROM PATENT TRIAL AND APPEAL BOARD IN IPR PROCEEDING.CONCERT PHARMACEUTICALS INC - DISAPPOINTED IN OUTCOME FROM PATENT TRIAL AND APPEAL BOARD IN IPR PROCEEDING.CONCERT PHARMACEUTICALS INC - INTEND TO APPEAL DECISION AS WE WORK TO CREATE ADDITIONAL INTELLECTUAL PROPERTY PROTECTING CTP-543.CONCERT PHARMACEUTICALS INC - DEVELOPMENT TIMELINES FOR CTP-543 REMAIN ON TRACK..CONCERT PHARMACEUTICALS INC - DECISION IS SPECIFIC TO CERTAIN PATENT CLAIMS COVERING CTP-543 AND DOES NOT AFFECT OTHER PROGRAMS IN PORTFOLIO.

Concert Pharmaceuticals Reports Year Ended 2018 Financial Results

Feb 28 (Reuters) - Concert Pharmaceuticals Inc <CNCE.O>::CONCERT PHARMACEUTICALS REPORTS YEAR ENDED 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL PROGRAMS.CONCERT PHARMACEUTICALS INC - CTP-692 POISED TO ADVANCE INTO PHASE 2 DEVELOPMENT BY YEAR END 2019 AS ADJUNCTIVE TREATMENT FOR SCHIZOPHRENIA.CONCERT PHARMACEUTICALS INC - REVENUE WAS $10.5 MILLION FOR YEAR ENDED DECEMBER 31, 2018, COMPARED TO $143.9 MILLION FOR YEAR ENDED DECEMBER 31, 2017.

Concert Pharmaceuticals Reports Positive Results For CTP-543

Nov 12 (Reuters) - Concert Pharmaceuticals Inc <CNCE.O>::CONCERT PHARMACEUTICALS REPORTS POSITIVE CTP-543 RESULTS FROM INTERIM ANALYSIS OF PHASE 2A TRIAL IN PATIENTS WITH ALOPECIA AREATA.CONCERT PHARMACEUTICALS INC - CTP-543 ACHIEVED ITS PRIMARY ENDPOINT IN 8 MG TWICE-DAILY COHORT.CONCERT PHARMACEUTICALS INC - NO SERIOUS ADVERSE EVENTS WERE REPORTED.CONCERT PHARMACEUTICALS - RESULTS FROM COMPLETE CTP-543 PHASE 2A TRIAL, INCLUDING 12 MG COHORT, EXPECTED IN Q3 2019.

Concert Pharmaceuticals Reports Q3 2018 Financial Results

Nov 1 (Reuters) - Concert Pharmaceuticals Inc <CNCE.O>::CONCERT PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q3 LOSS PER SHARE $0.74.Q3 EARNINGS PER SHARE VIEW $-0.63 -- THOMSON REUTERS I/B/E/S.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up